As Dr. Thomas Kuhn, a former physics professor at Harvard and Berkeley, taught in his book, The Structure of Scientific Revolutions, scientific fields undergo periodic “paradigm shifts” rather than progressing in a linear and continuous way, and that these paradigm shifts lead to new approaches in understanding what scientists would never have considered valid before. Such a paradigm shift is now underway for drugs and therapeutics, and has been described as “Systems Therapeutics for Physiological Renormalization.” Until now, the paradigm for drug and therapeutic development has been reductionistic, where a small molecules was developed to target one pathway in an attempt to remedy the diseases or condition. Goodman and Gilman’s The Pharmacological Basis of Therapeutics, long believed to be the oracle for teaching pharmacology to physicians and other practitioners, taught that “the small molecule had to specifically hit its target, and only its one target.” That is, develop a drug that specifically hits one target, and only one target, and that is the best way for drug development. However, most diseases and conditions involve many perturbed pathways, and a drug that targets only one of these many pathways is a drug doomed to failure or suboptimal therapeutic effect. Such is the case for well over 50% of the FDA-approved drugs on the market today, they don’t work. The drugs that don’t work include many cancer drugs, that are toxic and only cause harm. While this problem has received media attention, the world’s largest lobby, the medical-industrial complex, drowns out these reports by saturating the media with drug propaganda. This problem only became worse when physicians, such as Francis Collins, ushered in genomic fashionistaism, teaching that the small molecules should not only hit just one target, but that the target should be at the level of the genome. As Dr. Stephen Rappaport, Ph.D. at Berkeley teaches us, over 90% of diseases are caused by our exposome and the genome is not the underlying cause. Yet, Collins in all of his ignorance, called for genetically sequencing everyone, carrying your genetic sequence on a card that can be read by physicians, such that the physician can then treat you based on the information contained on your “genomics card.” Another physician, Leroy Hood, was quoted as saying, ” your entire genome and medical history will be on a credit card. You just put it in there [a computer] and a physician will instantly know what he’s dealing with.” Besides irrational thought underlying Collin’s call for a “genome card,” fraud was in his calling to make such ignorant claims. When found out, Collins said, “the significance and the scope of the fabrication in this circumstance, of which I had not the slightest idea, began to be very apparent.” In other words, Collins had no idea what was going on in his lab, and was attaching his name to “scientific papers” of which he had nothing to do with. This is called “ghostwriting,” where physicians put their names on “scientific papers” yet have had nothing to do with the study. The practice is rampant for practitioners, i.e. physicians. Leading other physicians astray, who control over 95% of biological research spending in the US given that physicians control the National Institutes of Health, Collins would cause biological research in the USA to be highly biased towards looking for diseases in all the wrong places – the genome. This bias continues today and has been taken to such an absurd level that almost every gene studied has been linked to a disease. Further upsetting those who believe that mutations in the genome underlie disease, is that mutations in the genome don’t happen just by chance, but are driven by environmental influences. Basically, one’s health status is not only influenced by your current environment acting at the protein level of your body, but also by what your ancestors experienced in their environments acting on their genetics and epigenetics. So what you do in life, including your diet, directly effects your health and can cause most diseases, but also will have consequences to your children and their children. As such, when what one has experienced in life disrupts their physiology, mostly acting at the protein level of the body, the resulting disease can be treated by renormalizing the physiology. This means, renormalizing the protein (and other molecules such as lipids) content of the afflicted tissues. As an example of the therapeutic benefit of this “systems therapeutic for physiological renormalization” approach, our group has demonstrated its efficacy in the skin for a number of conditions, including radiation dermatitis in cancer patients. The approach was also shown by Maguire and colleagues to be effective in protecting the nervous system from neurodegenerative diseases in an experimental animal model. The safety of this technology has been demonstrated, and the mechanism of action partially described. The approach has also been discussed in an interview of Dr. Greg Maguire by Dr. Tom Kleyman of the Physiological Society. Dr. Maguire has also recently described in a journal publication, Human Vaccines and Immunotherapeutics, how the “systems therapeutics for physiological renormalization” approach may help to make safer and more efficacious vaccines, helping to better prevent the spread of the disease. Stay tuned, there is much more to come, including our approach in treating immune and autoimmune conditions as I began to describe in my 2021 paper.